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Abstract
Background Cholangiocarcinoma (CCA) is becoming a common fatal hepatic tumor. Early detection of CCA is hampered by
the absence of a sufficiently accurate and noninvasive diagnostic test. Proteomic analysis would be a powerful tool to identify
potential biomarkers of this cancer.
Aims This study aims to identify new protein markers that are specific for CCA using proteomic approaches and to evaluate
the performance of S100 calcium-binding protein A9 (S100A9) and chaperonin-containing TCR1, subunit 3 (CCTγ) as
diagnostic markers for screening test of CCA.
Methods Two-dimensional differential gel electrophoresis (2-D DIGE) coupled with matrix-assisted laser
desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry were used to analyze and screen biomarker candidates
in the proteomes of five human CCA samples and five healthy control samples. Subsequently, two potential biomarkers,
S100A9 and CCTγ, were chosen for validation and analysis by immunohistochemical methods using CCA tissue
microarrays.
Results Twenty protein spots were significantly elevated and five protein spots were downregulated in all patients (p<0.05).
The positive rate was significantly higher in patients with CCA (48±35 %) compared with the normal liver control group (5±
10 %, p<0.001), the hepatocellular carcinoma group (15±20 %, p<0.001), and the cirrhosis group (12±16 %, p<0.001). A
greater proportion of patients with CCAwere positive for CCTγ (72±18 %) compared with the normal liver control group (43±
22 %, p<0.001), the hepatocellular carcinoma group (45±20 %, p<0.001), and the cirrhosis group (39±25 %, p<0.001).
Conclusions Combined comparative proteomic analysis using 2-D DIGE and MALDI-TOF is an effective method for
identifying differentially expressed proteins in CCA tissues. The expression of S100A9 and CCTγ showed promise as novel
diagnostic markers for CCA.
Keywords Liver cancer .Cholangiocarcinoma . 2-DDIGE .
Proteomics . S100 A9 . CCTγ
Introduction
Cholangiocarcinoma (CCA) is a malignant tumor that orig-
inates from the bile duct epithelium. Among primary liver
tumors, CCA accounts for an estimated 15 % of primary
liver cancers worldwide1 and is becoming a common type of
fatal hepatic tumor. CCA is responsible for more than 60 %
of liver tumors in parts of Southeast Asia, especially in
northeastern Thailand. Tumor stage, resectability, and sur-
vival are all closely correlated in patients with bile duct
carcinoma, suggesting that early detection strategies may
improve the prognosis of patients with this disease.2,3
However, early detection of CCA is hampered by the ab-
sence of a sufficiently accurate and noninvasive diagnostic
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test.4 Carcinoembryonic antigen (CEA) and carbohydrate
antigen 19-9 (CA19-9) are used as markers for early-stage
biliary carcinoma in patients. CEA is nonspecific and can be
elevated in the setting of other gastrointestinal or gyneco-
logic malignancies or other bile duct pathologies, such as
cholangitis and hepatolithiasis.5 The sensitivity and specificity
of CA19-9 are 53–89 and 80.5–86.0 %, respectively.6,7
Several biliary markers, including MMP-9, MMP-7, Mac-2-
binding protein, and the transcriptional repressor Slug, have
shown promise in the diagnosis of CCA.7–10
In recent years, proteomic analysis has been considered a
powerful tool for investigating cancer mechanisms.11
Combined comparative proteomic analysis by two-
dimensional differential gel electrophoresis (2-D DIGE)
and matrix-assisted laser desorption/ionization time-of-
flight mass spectrometry (MALDI-TOF-MS) is an effective
method for identifying differentially expressed proteins.12,13
In this study, we identified several proteins that were elevat-
ed or downregulated in CCA compared with normal liver using
a 2-D DIGE approach. Some of these proteins may be bio-
markers for early diagnosis, prognosis, or monitoring in the
therapy of CCA. Two of these proteins, chaperonin-containing
TCP1 subunit 3 (γ) (CCTγ) and S100 calcium-binding protein
A9 (S100A9), were measured using tissue microarrays to eval-
uate their performance as diagnostic markers for CCA.
Materials and Methods
Patients and Samples
The study design was approved by the independent ethics
committee of Ruijin Hospital, and the procedure was de-
scribed in detail to all patients before admission and informed
consent was obtained. The human liver tissue samples used
for 2D-DIGE were obtained from seven surgical patients
(mean age 62 years) in Ruijin Hospital who had a clinical
diagnosis of CCA between January 2008 and June 2009.
These patients included four intrahepatic cholangiocarcinoma
cases and three hilar cholangiocarcinoma cases. Two cases
that were hepatoma by pathologic diagnosis were excluded
from this study. Human liver tissue samples from five patients
(mean age 57 years) with a pathologic diagnosis of cholangitis
between January 2009 and June 2009 were used as controls.
The specimens were quickly removed during surgery and
stored immediately in liquid nitrogen until later experiments.
For immunohistochemistry, formalin-fixed, paraffin-
embedded biliary carcinoma tissue samples and control
samples were obtained from the surgical pathology archives
of the Department of Pathology at the Ruijin Hospital of
Shanghai Jiao Tong University. Forty CCA patients (26 men
and 14 women) aged 41–80 years (mean, 62.5±11 years)
underwent liver resection at the Ruijin Hospital of Shanghai
Jiao Tong University (China) from 2007 to 2009. Tissue
samples were collected from patients with intrahepatic
biliary cystadenocarcinoma (n=5), patients with
intrahepatic cholangiocarcinoma (n=17), patients with hi-
lar cholangiocarcinoma (n=14), and patients with
hepatobiliary cystadenoma (n=4), and 30 patients with
hepatocellular carcinoma, 30 patients with cirrhosis, and
10 normal liver tissues were collected as control group.
2-D DIGE and Image Analysis
This study was followed the standard methods of two-
dimensional differential gel electrophoresis proteomics
technology.14 These tissues were cut into 3 mm3 pieces and
digestedwith 1ml DIGE lysis buffer. The digested samples were
homogenized with Dounce Tissue Grinders, vortexed, sonicated
at 4 °C, and placed on ice. Extracts were centrifuged at 14,000×g
for 1 h, and the supernatants were collected. A pooled internal
standard to control for gel-to-gel variation was prepared by
mixing an equal amount of all tumoral and non-tumoral samples
that had been diluted to 5 μg/μl. A total of 50 μg of tumoral and
non-tumoral protein extracts with a pH of 8.9–9.0 were mini-
mally labeled with cyanine fluorochrome 3 (Cy3) or Cy5, and
the pooled internal standard was labeled with Cy2.
Three Cy-labeled protein samples (tumoral, non-tumoral,
and internal standard) were mixed. The mixtures were added
to an equal volume of sample buffer. All of the samples were
mixed, and the volume was adjusted to 250 μl with rehydra-
tion buffer. The first dimension was performed on an Ettan
IPGphor Isoelectric Focusing System (GE Amersham) using
13 cm immobilized pH gradient strips with a pH of 3–10.
After isoelectric focusing, the gel strips were then equilibrated
in equilibration buffer. The equilibrated strips were loaded on
the top of a 12.5 % sodium dodecyl sulfate-polyacrylamide
gel electrophoresis gel. Electrophoresis was performed using a
Hoefer SE 600 unit (GE, Amersham Biosciences). After 2D-
DIGE, the gels were scanned with an UMax PowerLook
2100XL (GE, Amersham Biosciences). The excitation and
emission wavelengths for Cy2, Cy3, and Cy5 are 488/520,
532/580, and 633/670 nm, respectively.
MS
After scanning, the gels were stained using the Coomassie Blue
Staining method. The protein spots were cut from gels
destained by washing in MilliQ distilled water. After trypsin
digestion and evaporation, the MALDI-TOF/MALDI-TOF-
TOF analyses (Bruker Daltonics, Bremen Germany) were
performed to acquire mass spectra for all the peptides. Tryptic
digests were prepared in an AnchorChip sample plate (Bruker
Daltonics) according to the manufacturer’s protocol. MS data
were acquired with an N2 laser at a sampling rate of 25 Hz. The
tryptic peptide mass maps were transferred with the MS
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BioToolsTM program (Bruker Daltonics) using MASCOT
software (Matrix Science). Then, the National Center for
Biotechnology Information (NCBI) non-redundant database
was searched with human as the taxonomy.
Proteins were unambiguously identified through their
peptide mass fingerprinting (PMF) and MS/MS ion search
using MASCOT to interrogate the NCBI Inr 20090820
(9511482 sequences; 3251602805 residues). The ion score
is −10×Log (P), where P is the probability that the observed
match is a random event. Individual ions scores greater than
a certain number indicate identity or extensive homology (p
<0.05). The protein scores are derived from ion scores as a
non-probabilistic basis for ranking protein hits. Protein
scores >66 are considered statistically significant (p<0.05)
under the parameters described previously.
S100A9 and CCTγ Tissue Microarrays
Tissue microarrays were constructed as described previously.15
For the immunohistochemical analysis, the tissue microarrays
were deparaffinized in xylene and graded ethanols, washed
with three times with PBS, and boiled in citrate buffer (antigen
retrieval solution; DAKO, Carpinteria, CA). Endogenous per-
oxidases were blocked by incubation and incubation overnight
with mouse antihuman monoclonal antibody. After washing,
biotin and a streptavidin–horseradish peroxidase conjugate
were applied. The peroxidase reaction was visualized by ap-
plying diaminobenzidine tetrahydrochloride (DAB) containing
hydrogen peroxide (Liquid DAB Substrate Chromogen
System; DAKO); sections were subsequently developed by
washing bywater, counterstainedwith hematoxylin, dehydrated,
and mounted.
Immunohistochemical staining intensity and area were
assessed by two observers and were expressed as the staining
intensity of positive carcinoma. Staining intensity was scored as
negative, *1, 1, 2, and 3, which represent negative, weakly
positive, mildly positive, moderately positive, or strongly posi-
tive. The staining area was scored as negative (without staining),
*1 (weak yellow staining), 1 (light brown staining), 2 (yellow or
brown staining), or 3 (dark yellow or dark brown staining). The
positive rate of the microarrays was calculated as the percentage
of positively stained carcinoma cells among all cells.
Statistical Analysis
All statistical analyses were performed using SPSS 13.0 soft-
ware (SPSS, Chicago, USA). After 2D-DIGE, three images
corresponding to three samples labeled with three different Cy
dyes were generated in one gel. A t test was performed for
every matched spot set, comparing the average and SD of
protein abundance for a given spot. Pixel values from images
of a small area of fluorescent-stained gels were converted into
3-D representations to illustrate the differential quantification
between the two groups.
Differences between S100A9 and CCTγ expression in
tumoral tissues and control group were analyzed using a
paired Student’s t test. An receiver operating characteristic
(ROC) curve was generated by plotting the sensitivity
against 1-specificity, and the area under the curve with
95 % confidence intervals (CI) was calculated. The optimal
cutoff points for S100A9 and CCTγ were selected based on
the ROC curve analysis. The sensitivity, specificity, positive
predictive value, and negative predictive value were calcu-
lated using a 2×2 table of the collected data.
Results
Analysis of Differentially Expressed Proteins
Tissue samples collected from five patients with CCA and
five normal controls were run on 2-D DIGE to elucidate
changes in protein expression between tumors and normal
controls (Fig. 1). The average ratio and p for a given spot
between patients and normal controls was calculated, and
these values are shown in Table 1. Using the biological
variation analysis module of the DeCyder software, 25
differentially expressed proteins were selected. Twenty pro-
teins were significantly elevated in all patient groups (with
average ratios from −1.60 to −4.47), while five proteins

























Fig. 1 Representative 2D gel images indicating the differential spots
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from 1.35 to 2.16), and the statistical variance of the tumor
versus the normal spot volume ratios was within the 95 %
confidence level (Student’s t test; p<0.05) (Table 1).
Identification of Differentially Expressed Proteins
Sixteen protein spots were selected for tryptic digestion and
MALDI-TOF or MALDI-TOF/TOF analysis. Fortunately, 13
out of 16 proteins were unambiguously identified (Fig. 2 is the
Mascot score schematic diagram of two of all the identified
proteins). Three proteins (644, 898, and 1327) were identified
by PMF. The other ten proteins were searched by MS/MS ion
search. Eleven protein spots were upregulated and two protein
spots were downregulated in patients (Table 2).
S100A9 and CCTγ Immunohistochemistry
S100A9 and CCTγ expression was measured by immuno-
histochemistry in tissue samples from 40 patients with CCA,
30 patients with hepatocellular carcinoma, 30 patients with
cirrhosis, and 10 normal liver tissues. S100A9 was detected
in 37 of 40 tumor tissue samples (92.5 %). Staining scores
of *1–1 (weak–mildly positive), 1 (mildly positive), 1–2
(mild–moderately positive), and 2 (moderately positive)
were found in 2, 23, 9, and 3 tumor tissue samples, respec-
tively. Positive S100A9 staining (>5 % of carcinoma cells
stained) was observed in the cytoplasm of carcinoma cells
(Fig. 3a). S100A9 was expressed only in three out of ten
normal tissue samples (Fig. 3b), 14 out of 30 hepatocellular
carcinoma samples (Fig. 3c), and 12 out of 30 cirrhosis
samples (Fig. 3d). The positive rate was significantly higher
in patients with CCA (48±35 %) compared to the normal
liver control group (5±10 %, p<0.001), the hepatocellular
carcinoma group (15±20 %, p<0.001), and the cirrhosis
group (12±16 %, p<0.001).
CCTγ was also detected in 37 of 40 tumor tissue samples
(92.5 %). Staining scores of *1–1 (weak–mildly positive), 1
(mildly positive), 1–2 (mild–moderately positive), and 2
(moderately positive) were found in 3, 14, 14, and 6 tumor
tissue samples, respectively. Positive CCTγ staining (>10 %
of carcinoma cells stained) was observed in the cytoplasm of
carcinoma cells (Fig. 4a). CCTγ had low levels of expres-
sion in normal tissue samples (Fig. 4b), hepatocellular car-
cinoma tissue samples (Fig. 4c), and cirrhosis samples
(Fig. 4d). Staining scores of 1 and 1–2 were found in eight
and two normal tissue samples, respectively, and the positive
rate was significantly higher in patients with CCA
(72±18 %) compared to the normal liver control group (43±
Table 1 Differentially expressed proteins, as determined by Student’s
t test between the normal control and tumor groups
Pos. Protein spots p value Average ratio
1 765 0.0054 −4.47
2 1532 0.0060 −4.46
3 755 0.0012 −3.66
4 885 0.0056 −3.55
5 1314 0.0023 −3.33
6 1283 0.0095 −3.27
7 1518 0.0020 −3.21
8 1015 0.00069 −2.65
9 1089 0.0042 −2.62
10 1290 0.0091 −2.47
11 644 0.0094 −2.46
12 1327 0.0043 −2.31
13 1116 0.0042 −1.97
14 1338 0.0097 −1.92
15 1322 0.0047 −1.89
16 1083 0.0013 −1.82
17 1082 0.0093 −1.78
18 871 0.0081 −1.69
19 898 0.0070 −1.69
20 610 0.0014 −1.60
21 439 0.0030 1.35
22 1255 0.0033 1.49
23 431 0.0020 1.83
24 334 0.0056 1.90
25 782 0.0085 2.16
Fig. 2 Mascot score schematic diagram: x-axis as Mascot score (pro-
tein score), the y-axis is the number of matching. Score that exceeds the
shaded area obtained positive identification (p<0.05). a The matching
and sequence coverage of protein no. 644 and protein ID gi|55960506
in database. b The matching and sequence coverage of protein no.
1518 and protein ID gi|4506773 in database
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Table 2 Differentially expressed proteins identified by MALDI-TOF after 2-D DIGE
Spot
no.






334 gi|28592 Serum albumin (Homo sapiens) 71316 6.05 3 65 2 K.YLYEIAR.R
K.KVPQVSTPTLVEVSR.N
610 gi|3420181 WDR1 protein (Homo sapiens) 58593 6.41 5 38 2 K.VFASLPQVER.G
R.LATGSDDNCAAFFEGPPFK.F
644 gi|55960506 Chaperonin-containing TCP1,
subunit 3 (γ) (Homo sapiens)









782 gi|4501901 Aminoacylase 1 (Homo sapiens) 46084 5.77 5 39 2 K.GPEEEHPSVTLFR.Q
K.VVNSILAFR.E
871 gi|5031777 Isocitrate dehydrogenase 3 (NAD+)
alpha precursor (Homo sapiens)
40022 6.47 8 108 3 K.APIQWEER.N
K.TPYTDVNIVTIR.E
R.IAEFAFEYAR.N
885 gi|1575000 2,4-Dienoyl-CoA reductase 36096 9.50 6 45 1 K.VAGHPNIVINNAAGNFISPTER.L
898 gi|62896849 N-acetylglucosamine kinase
variant (Homo sapiens)











1082 gi|4757768 Rho GDP dissociation inhibitor
(GDI) alpha (Homo sapiens)
23250 5.02 17 119 3 K.YIQHTYR.K
K.IDKTDYMVGSYGPR.A
R.AEEYEFLTPVEEAPK.G
1089 gi|539605 GTP-binding protein G25K
—human (fragments)
6419 6.34 23 42 1 R.IDKTDYMVGSYGPR.-
1314 gi|1421609 Chain A, X-ray structure of Nm23
human nucleoside diphosphate
kinase B complexed with GDP at
2 Å resolution
17290 8.55 20 45 3 R.TFIAIKPDGVQR.G
K.DRPFFPGLVK.Y
R.GDFCIQVGR.N








Anterior gradient 2 homolog (Homo
sapiens) chain A, X-ray structure
of Nm23 human nucleoside
diphosphate
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22 %, p<0.001), the hepatocellular carcinoma group (45±
20 %, p<0.001), and the cirrhosis group (39±25 %, p<0.001).
An ROC curve analysis (Fig. 5) was used to calculate an
area under the curve of 0.894 (95 % CI=0.825–0.962) for
S100A9 and 0.860 (95 % CI=0.779–0.942) for CCTγ.
When the cutoff value of S100A9 was set at 4 %, the
sensitivity and specificity for the diagnosis of CCA were
92.6 and 75 %, respectively. When the cutoff value for
CCTγ was set at 62.5 %, the sensitivity and specificity for
the diagnosis of CCA were 80.8 and 77.8 %, respectively.
Discussion
Detecting new biomarkers for early-stage biliary carcinoma
in patients may improve the prognosis of patients with
CCA. Due to the low incidence of CCA, a retrospective
study based on liver tissue is necessary for further research.
In this study, the analysis of the 2-D DIGE gels showed a
large number of differentially expressed proteins in CCA.
Some of these proteins are predicted to play roles in tumori-
genesis or tumor growth16–18 and may be potential biomarkers
in early screening test. S100A9 and CCTγ were detected by
immunohistochemistry in 50 tissue samples, and the expres-
sion was significantly elevated in patients with a diagnosis of
CCA when compared to control groups. It is shown that the
sensitivity and specificity of S100A9 were 92.6 and 75 %
when using a cutoff value of 4 %. The sensitivity and the
specificity of CCTγ, however, were 80.8 and 77.8 %, respec-
tively, when using a cutoff value of 4 %. The diagnostic
accuracy of S100A9 and CCTγ as biomarkers compared
favorably with the performance of other protein markers for
patients with biliary tract carcinoma (specifically, CEA,
CA125, CA19–9, and fibronectin), which have reported sen-
sitivities of 58–78 % and specificities of 33–84 %. This study










kinase B complexed with
GDP at 2 Å resolution
R.LYAYEPADTALLLDNMKK.A





1518 gi|4506773 S100 calcium-binding protein A9
(Homo sapiens)
13291 5.71 29 43 2 K.LGHPDTLNQGEFK.E
K.MHEGDEGPGHHHKPGLGEGTP.-
Fig. 3 a Immunoperoxidase
stains of a CCA case that is
positive for S100A9, ×400 (the
arrow points out a positive cell).
b Immunoperoxidase stains of a
non-CCA case that is negative
for S100A9, ×400. c
Immunoperoxidase stain of a
case of hepatocellular
carcinoma that is negative for
S100A9, ×400. d
Immunoperoxidase stain of
case of cirrhosis that is negative
for S100A9, ×400
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and CCTγ expression between CCA patients and control
patients.
The S100 family of proteins includes a group of small acidic
proteins with common EF-hand calcium-binding motifs. S100
proteins regulate a variety of cellular processes, including cel-
lular proliferation, differentiation, motility, secretion, mem-
brane permeability, protein synthesis, and extracellular signal
transduction. S100A8 and S100A9 are two members of the
S100 protein family. S100A8 and S100A9 are key
effectors/amplifiers of inflammation, with a wide range of
activities, including cytokine induction. Subsequently, it has
emerged as an important proinflammatory mediator in acute
and chronic inflammation. More recently, increased S100A8
and S100A9 levels were also detected in various human can-
cers, such as skin, colorectal, breast, prostate, and lung.19–22
Numerous studies demonstrate that the serum level of S100A9
is significantly elevated in many types of cancers, including
breast cancer, esophageal cancer, and lung cancer.23,24 A recent
report suggested the calcium-binding protein S100P is
upregulated in CCA. S100P was frequently expressed in the
CCA tissues but not in the normal bile duct. The brushing
cytology samples from the CCA cases revealed increased ex-
pression of S100P compared with the benign biliary strictures.
The relative expression level of S100P could identify CCA at a
higher sensitivity than classical cytology, and the combination
of the S100P expression level and cytology yielded a sensitivity
of 90.0 %, with a specificity of 92.0 %.25
The chaperonin-containing t-complex polypeptide 1 (CCT),
also called TRiC or c-cpn, mediates protein folding in the
cytosol. CCT is a member of the chaperonin family, which
includes mitochondrial Hsp60, bacterial GroEL, plastid
Rubisco subunit-binding protein, and archaea group II
chaperonins.26,27 CCTshows a double-torus-like structurewith
eightfold rotational symmetry, and the complete complex is
assembled from 16 subunits. The chaperonins are key molec-
ular complexes that are essential in protein folding to produce
stable and functionally competent protein conformations.28,29
One member of the chaperonin group of proteins is TCP1
Fig. 4 a Immunoperoxidase
stains of a CCA case that is
positive for CCTγ, ×200 (the
arrow points out a positive cell).
b Immunoperoxidase stains of a
non-CCA case that is negative
for CCTγ, ×200. c
Immunoperoxidase stain of a
case of hepatocellular
carcinoma that is negative for
CCTγ, ×400. d
Immunoperoxidase stain of






























Diagonal segments are produced by ties.
ROC CurveFig. 5 Receiver operating
characteristic (ROC) curve
analyses of S100A9 and CCTγ
for the diagnosis of
cholangiocarcinoma. The
diagnostic accuracy of each
biomarker, in terms of its
sensitivity and specificity, were
presented by ROC curve
analysis. a and b correspond to
S100A9 and CCTγ. Only the
area under the curve (AUC) of
the ROC is significantly higher
than a chance value (0.5)
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(chaperonin-containing t-complex polypeptide 1 or CCT).
Increased expression of cytosolic chaperonin CCT in human
hepatocellular and colonic carcinoma has been reported.18
Though proteomic approaches in CCA are currently at an
early stage, further research could be conducted to early diag-
nose or evaluate the prognosis. It is believed that varied protein
expression of different tumor location, size, lymphatic involve-
ment, degree of fibrosis, specific histology, etc. would also be
found in further research based on this study. Further experi-
ments are being conducted to contrast the expression of
S100A9 and CCTγ between CCA and HCC patients based on
bile or serum,which could be helpful in early diagnosis of CCA.
In conclusion, two potential biomarkers, S100A9 and
CCTγ, were found by proteomic screening and confirmed
by immunohistochemistry. Our research suggests that these
two proteins have the potential to be used as new tumor
markers for early detection of CCA. Further studies involv-
ing a larger patient population and serum S100A9 and
CCTγ levels are needed to provide more information re-
garding the diagnostic accuracy of S100A9 and CCTγ.
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